Generation and characterization of a high-affinity monoclonal antibody for MUC1 measurement in breast cancer

Hybridoma

Volumn 30, Issue 2, 2011, Pages 137-143

  Hamid, S S A ^a,b   Cheah, S H ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b MALAYSIAN NUCLEAR AGENCY   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN; MONOCLONAL ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; BIOREACTOR; BREAST CANCER; CANCER DIAGNOSIS; CANCER IMMUNIZATION; CANCER STAGING; CANCER THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; SUPERNATANT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BREAST NEOPLASMS; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYBRIDOMAS; IMMUNIZATION; IMMUNOGLOBULIN ISOTYPES; MICE; MICE, INBRED BALB C; MUCIN-1; TUMOR MARKERS, BIOLOGICAL;

MUS;

EID: 79955640387     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2010.0091     Document Type: Article

References (19)

1. Chye GLC, and Yahaya H: Second report of the National Cancer Registry: Cancer Incidence in Malaysia, 2003. 2004.
2. Patton S, Gendler SJ, and Spicer AP: The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophys Acta 1995;1241(3):407-423. (Pubitemid 26021828)
3. Perey L, Hayes DF, and Kufe D: Effects of differentiating agents on cell surface expression of the breast carcinomaassociated DF3-P epitope. Cancer Res 1992;52(22):6365-6370.
4. Perey L, Hayes DF, Maimonis P, Abe M, O'Hara C, and Kufe DW: Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res 1992;52(9):2563-2568.
5. Graham RA, Burchell JM, and Taylor-Papadimitriou J: The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Cancer Immunol Immunother 1996;42(2):71-80. (Pubitemid 26109524)
6. Acres B, Apostolopoulos V, Balloul JM, Wreschner D, Xing PX, Ali-Hadji D, Bizouarne N, Kieny MP, and McKenzie IF: MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother 2000;48(10):588-594. (Pubitemid 30004493)
7. Schuhmacher J, Klivenyi G, Kaul S, Henze M, Matys R, Hauser H, and Clorius J: Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET. Nucl Med Biol 2001;28(7):821-828. (Pubitemid 32900640)
8. Lundy J, Thor A, Maenza R, Schlom J, Forouhar F, Testa M, and Kufe D: Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients. Breast Cancer Res Treat 1985;5(3):269-276. (Pubitemid 15060454)
9. Hilkens J, Buijs F, Hilgers J, Hageman P, Calafat J, Sonnenberg A, and van der Valk M: Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 1984;34(2):197-206. (Pubitemid 14053141)
10. Agyei Frempong MT, Darko E, and Addai BW: The use of carbohydrate antigen (CA) 15-3 as a tumor marker in detecting breast cancer. Pak J Biol Sci 2008;11(15):1945-1948. (Pubitemid 352837375)
11. Galfre G, and Milstein C: Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol 1981; 73(Pt B): 3-46.
12. Goding JW: Antibody production by hybridomas. J Immunol Methods 1980;39(4):285-308. (Pubitemid 11205722)
13. Martin BM: Tissue Culture Techniques: An Introduction. Birkhauser, Boston, 1994.
14. Friguet B, Chaffotte AF, Djavadi-Ohaniance L, and Goldberg ME: Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods 1985;77(2):305-319. (Pubitemid 15103678)
15. Burchell JM, Mungul A, and Taylor-Papadimitriou J: O-linked glycosylation in the mammary gland: changes that occur during malignancy. J Mammary Gland Biol Neoplasia 2001;6(3):355-364.
16. Al-Azawai D, Kelly G, Myers E, Mcdernott EW, Hill ADK, Duffy M, and Higgins NO: CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer 2006;6(220).
17. Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, Colleoni M, Thurlimann B, Mendiola C, Aebi S, Price KN, Pagani O, Simoncini E, Gertsch MC, Gelber RD, Coates AS, and Goldhirsch A: CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol 2007;18:701-708. (Pubitemid 46523274)
18. Safi F, Kohler I, Rottinger E, and Beger H: The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer 1991;68(3):574-582.
19. Duffy MJ: Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 2006;52(3):345-351.